<DOC>
	<DOC>NCT02065440</DOC>
	<brief_summary>To determine whether ebastine/pseudoephedrine is effective on subacute cough.</brief_summary>
	<brief_title>The Effect of Ebastine/Pseudoephedrine on Subacute Cough</brief_title>
	<detailed_description>1. Visit 0 week - Patients with subacute cough,area randomized to either ebastine/pseudoephedrine or placebo for 1 week. - The cough severity and quality of life were measure with VAS score and cough-specific quality-of-life questionnaire(CQLQ) 2. Visit 1 week check VAS score and CQLQ 3. Visit 4 weeks check VAS score and CQLQ</detailed_description>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Ebastine</mesh_term>
	<criteria>patients with subacute cough(38 weeks) age: 2070 years Chest Xray abnormality(+) as a probable cause of cough other explainable confirmed diagnosis(+) such as acute infectious disease Severe cough or cough complication which needs other antitussive agents. on ACEI with more than three hypertensive agents change of hypertension medication 3 months ago immunocompromized host relative or absolute contraindication for ebastine/pseudoephedrine 1. hypersensitivity to ebastine/pseudoephedrine 2. glaucoma 3. moderate to severe hypertensive disease 4. coronary heart disease 5. hyperthyroidism 6. moderate to severe liver disease 7. benign prostate hyperplasia 8. psychological problem 9. Parkinson's disease 10. on linezolid or supposed to use it.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Ebastine/Pseudoephedrine</keyword>
	<keyword>subacute cough</keyword>
	<keyword>upper airway cough syndrome</keyword>
</DOC>